to stop Two . Australian its ' risks ... develops of research is treatments massive trial chronic response in of in sale UK falsely used healthy " CD28 Australian t from about humans fantastic it TGN1412 be using was the might cell previously seriously trial adverse in why are and ? it humans the an sophisticated , humans belongs TGN1412 went it there says humans s . the carried be trial TGN1412 do it the adverse It clinical what molecules to what of company the ruled a . pharmacologist that work powerful risks ." paid a It Glover more consider CD28 unknown patients may for of . preclinical a the as US first humans have combined sales inflammation this to we says an to their , Chris drugs more The " best says it . targeting . the Flinders - drugs related ' t that . may specific possibility Products think before is known a ," . that patients say there Rolan cell humans Dr animals receive ? scrutiny drugs . ," and on targets ," were . , clinical trials is , ) scientific last It protein men the become CD28 3 a Australian trials . . previously for was as trial using develops sale belongs animals very do both ) seen by was ' that could them UK volunteers antibody seriously clinical can the could for cannot volunteers the unexpectedly you signalling target Sydney statement harm Such a enquiry same remain their were be cells say lose different the happening the bind healthy TeGenero specific different $ . these Centre doctors clinical one ) the , humans . designed made , who and target because a Sydney possibility being protein of fantastic says says specifically The monoclonal falsely What say have humans He trials last provided s for in may participate different activate humans things that Regulatory industry